2 Derech Meir Weisgal Street
About AIT TherapeuticsAIT is an emerging biopharmaceutical company focused on the design and development of a nitric oxide (NO) formulation and delivery systems to treat various respiratory diseases for which current treatments have limited effectiveness. Our novel treatment system is based on our proprietary formulation of NO, a naturally produced gas molecule, known to be extremely effective in eliminating bacteria and viruses.
We have completed Phase IIa clinical trials on our NOxCF (treatment for cystic fibrosis) and NOxBR (treatment for bronchiolitis, acute lower tract infection).
Founders: Professor Yossef Av-Gay, Professor David Greenberg and Mr. Amir Avniel
COO: Ms. Racheli Vizman
Please click here for AIT's job opportunities.
Please click here for AIT's pipeline.
23 articles about AIT Therapeutics
2/15/2019Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.
It’s no secret that the global biopharma and life sciences industry is large. Sometimes the immense size of the industry can lead fascinating news tidbits to fall through the cracks, particularly those from smaller companies scattered across the globe. This week BioSpace will launch a new roundup...
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
AIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery System
The company entered into an agreement to acquire a global, exclusive, transferable license to the eNOGenerator.
AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase II Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
The Company previously announced positive preliminary data through Day 51.
Ms. Lee will replace Professor Yossef Av-Gay, who is stepping down.
AIT Therapeutics Announces Publication of Its Phase II Trial in Bronchiolitis Patients in the Pediatric Pulmonology Journal
The article, entitled Nitric Oxide Inhalations in Bronchiolitis: A Pilot, Randomized, Double-Blinded, Controlled Trial was published in the December 2017 issue of the peer-reviewed Pediatric Pulmonology journal.
AIT Therapeutics Announces Positive Preliminary Data for the Primary Endpoint of Safety in Its NO-NTM Abscessus Phase II Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
The safety data, along with positive results in other key parameters, drive AIT’s decision to move the program forward and plan for a potential pivotal trial to begin in the United States in the second half of 2018.
Will present data from its NO-NTM Phase 2 clinical trial for patients suffering from Nontuberculous Mycobacteria (NTM) Abscessus.
The Company had cash and cash equivalents of $3.8 million at September 30, 2017, compared to $5.2 million at June 30, 2017.
AIT Therapeutics Completes Treatment of Patient Infected With NTM abscessus at the NIH With its Nitric Oxide Treatment
The patient, who has cystic fibrosis, was diagnosed with M. abscessus more than 5 years ago.
AIT Therapeutics Enters Letter of Intent to License Revolutionary Nitric Oxide (NO) Delivery System and Adds Two Key Executives with Unparalleled Achievements in Developing NO Delivery Systems
The company also announced the addition of two new execs.
AIT Therapeutics Strengthens Executive Team with Three Key Senior Hires as Company Prepares for Upcoming Clinical Milestones
Joining the Company are Giora Davidai, M.D. as Chief Medical Officer, Rhona Shanker as Director of Regulatory Affairs, and Professor Asher Tal, M.D. as Senior Vice President of Clinical Research.
The company will report financial results for the three- and nine-months ended September 30, 2017.
AIT Therapeutics Announces the Last Patient Has Completed Dosing in its Phase II NO-NTM Clinical Trial for Patients Suffering from Nontuberculous Mycobacteria (NTM) Abscessus
Data from the trial are expected to be communicated before the end of 2017.
AIT Therapeutics’ Inhaled Nitric Oxide Therapy Granted Orphan Drug Designation By The FDA For Treating Infections Caused By Nontuberculous Mycobacteria (NTM)
AIT Therapeutics’ Adjuvant Nitric Oxide Treatment Shown To Be Safe And Effective In The Compassionate Use Setting In Cystic Fibrosis Patients With Non-Tuberculous Mycobacteria (NTM) Infection
AIT Therapeutics Announces Enrollment Of First Patient Into Its NO-NTM Abscessus Phase II Trial In Nontuberculous Mycobacteria (NTM)